New Study: Sativex Shows Promise As Potential Therapy for Treatment Resistant Tourette Syndrome

Cannabinoids accomplish what Western medicine can’t – again!

While approximately 138,000 American kids suffer from Tourette syndrome (TS) – roughly 1 in every 162 adolescents under the age of 17 – a single case study on treatment resistant Tourette syndrome indicates that cannabinoids may provide a therapeutic option; offering a hopeful light at the end of an otherwise bleak tunnel.

Screen Shot 2016-08-26 at 6.55.01 AM

Theoretically also addressing the myriad of occurring co-conditions that have been identified in 86% of the children diagnosed with TS, the subject of the single case study was given 10.8 mg Tetrahydrocannabinol (THC) and 10 mg cannabidiol (CBD) twice daily. Common among children diagnosed with Tourette’s syndrome, 63% suffer from ADHD, 49% suffer from anxiety, 25% depression, and 35% autism.

Occurring co-conditions with Tourette's syndrome... read more at: